AI Terminal
Kuros Biosciences Ltd.
Board/Management Information • Mar 8, 2016
916_rns_2016-03-08_f3ea0718-6cd8-42ae-aad6-131c7a668a63.html
Board/Management Information
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 8 March 2016 07:00
Kuros Biosciences Ltd. appoints Chief Medical Officer
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Change of Personnel
2016-03-08 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.
Kuros Biosciences Ltd. appoints Chief Medical Officer
Schlieren (Zurich), Switzerland, March 8, 2016 – Kuros Biosciences Ltd. (“Kuros” or the “Company”), announced today that Dr. Virginia Jamieson has been appointed Chief Medical Officer and member of the Executive Board with immediate effect.
Dr. Jamieson has spent over 25 years in the pharmaceutical industry and has considerable experience in early and late stage clinical development, product registration and medical affairs. Dr. Jamieson received her medical degree at Edinburgh University and obtained a postgraduate fellowship in anesthesia from the Royal College of Surgeons in London. In addition, she has a diploma from the Faculty of Pharmaceutical Medicine where she has also been an appraiser for revalidation of physicians in the pharmaceutical industry. Dr. Jamieson already worked for Kuros from 2005 to 2012 as Medical Director and then as Chief Medical Officer and is therefore very familiar with Kuros’ products.
Didier Cowling, CEO of Kuros, said: “We are delighted to have Virginia join us again. Her wealth of experience, both in the surgical field and pharmaceutical and medical industry, coupled with her deep knowledge of Kuros’ products, makes this a key appointment for us.”
For further information, please contact:
Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
About Kuros Biosciences Ltd
Kuros Biosciences Ltd is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol KURN.
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
End of ad hoc announcement
+++++
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=CXTXQEOIJL
Document title: Kuros_CMO_160308
2016-03-08 News transmitted by EQS Schweiz AG. www.eqs.com – news archive: http://switzerland.eqs.com/de/News
The issuer is responsible for the contents of the release.
| Language: | English |
| Company: | Kuros Biosciences AG |
| Wagistrasse 25 | |
| 8952 Schlieren | |
| Switzerland | |
| Phone: | +41 44 733 4747 |
| Fax: | +41 44 733 4740 |
| E-mail: | [email protected] |
| Internet: | www.kuros.ch |
| ISIN: | CH0011025217 |
| Valor: | – |
| Listed: | Foreign Exchange(s) SIX |
| End of News | EQS Group News Service |